Skip to main content




) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.4%. By the end of trading, GlaxoSmithKline rose 35 cents (0.8%) to $44.11 on average volume. Throughout the day, 3.1 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.1 million shares. The stock ranged in a price between $43.77-$44.32 after having opened the day at $44.25 as compared to the previous trading day's close of $43.76. Other companies within the Health Care sector that increased today were:

Prima Biomed Ltd. ADR



), up 23.5%,

Synta Pharmaceuticals



), up 15.6%,

Theragenics Corporation



), up 15%, and

Scroll to Continue

TheStreet Recommends




), up 14.9%.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $112.09 billion and is part of the


industry. The company has a P/E ratio of 13.4, below the average drugs industry P/E ratio of 14.1 and below the S&P 500 P/E ratio of 17.7. Shares are down 4.1% year to date as of the close of trading on Wednesday. Currently there are six analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Chelsea Therapeutics International



), down 31.3%,

ARCA biopharma



), down 21.7%,




), down 17.4%, and

Sunshine Heart



), down 16.5%, were all losers within the health care sector with

Watson Pharmaceuticals



) being today's health care sector loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care